# Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

> **NCT04956302** · PHASE1 · TERMINATED · sponsor: **Abdullah Khan** · enrollment: 1 (actual)

## Conditions studied

- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Daratumumab and Hyaluronidase-fihj
- **DRUG:** Dexamethasone
- **DRUG:** Panobinostat Lactate

## Key facts

- **NCT ID:** NCT04956302
- **Lead sponsor:** Abdullah Khan
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-27
- **Primary completion:** 2022-06-16
- **Final completion:** 2022-06-16
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** PI Decision
- **Last updated:** 2024-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04956302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04956302, "Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04956302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*